Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel.
Paclitaxel was recently recognized as an active chemotherapeutic agent for acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma (KS). However, the best way to administer paclitaxel in AIDS-KS patients remains unknown. Herein, we reported an AIDS-associated KS patient whose disease progressed on the first-line chemotherapy with doxorubicin and bleomycin, but later responded well to weekly 1-hour infusion of 70 mg/m2 paclitaxel. It is particular noteworthy that this weekly dosing schedule resulted in almost negligible toxicities. The authors suggested a prospective study of weekly paclitaxel for AIDS-KS should be started as soon as possible.
Hsu
C H
CH
Department of Oncology, National Taiwan University Hospital, Taipei.
Chen
M Y
MY
Cheng
A L
AL
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011899:Ranitidine / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D000972:Antineoplastic Agents, Phytogenic; D003907:Dexamethasone; D011899:Ranitidine; D004155:Diphenhydramine; D017239:Paclitaxel